OMLYCLO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OMLYCLO (OMLYCLO).
OMLYCLO (omalizumab) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It inhibits the binding of IgE to the high-affinity FcεRI receptor on mast cells and basophils, thereby reducing the release of mediators of the allergic response.
| Metabolism | Omalizumab is a monoclonal antibody that undergoes degradation via the reticuloendothelial system (RES) and is catabolized to small peptides and amino acids. It is not metabolized by cytochrome P450 enzymes or excreted renally. |
| Excretion | Primarily renal excretion (70-80% as unchanged drug) and fecal/biliary elimination (20-30%). |
| Half-life | Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 4-8 hours in renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 90% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.5-1.0 L/kg, indicating moderate tissue distribution. |
| Bioavailability | Oral: 80-90% (first-pass metabolism minimal). |
| Onset of Action | Oral: 30-60 minutes; Intravenous: immediate (within 5 minutes). |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; duration may be extended in hepatic or renal dysfunction. |
| Molecular Weight | 598.64 |
For seasonal trivalent inactivated influenza vaccine (IIV3): 0.5 mL intramuscularly as a single dose.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for any degree of hepatic impairment. |
| Pediatric use | Children 6 months through 8 years: 0.5 mL intramuscularly; if receiving influenza vaccine for the first time, administer 2 doses at least 4 weeks apart. Children 9 years and older: 0.5 mL intramuscularly as a single dose. |
| Geriatric use | Adults 65 years and older: 0.5 mL intramuscularly as a single dose; no specific dose adjustment needed, but consider age-related immune response and comorbidities. |
| 1st trimester | Avoid due to teratogenic risk; consider alternative antineoplastic agents. |
| 2nd trimester | Avoid; may cause fetal harm based on animal studies. |
| 3rd trimester | Avoid; potential for neonatal toxicity. |
Clinical note
Comprehensive clinical and safety monograph for OMLYCLO (OMLYCLO).
| Placental transfer | Yes, crosses placenta; human data limited but animal studies confirm transfer. |
| Breastfeeding | Not recommended; potential for serious adverse reactions in nursing infants. Discontinue drug or nursing. |
| Lactation Rating | L5 |
■ FDA Black Box Warning
Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema, has been reported after administration of OMALYZE (omalizumab). Anaphylaxis has occurred as early as after the first dose, but also after months and years of treatment. Patients should be observed for a period of time after administration and be educated about the signs and symptoms of anaphylaxis.
| Serious Effects |
Hypersensitivity to omacetaxine mepesuccinate or any excipientSevere neutropenia (absolute neutrophil count < 500 cells/mm³)Severe thrombocytopenia (platelet count < 50,000/mm³)Pregnancy
| Precautions | Anaphylaxis risk: observe patients for at least 2 hours after injection, Malignancy: rare reports of malignancies; monitor for signs, Eosinophilic conditions: Churg-Strauss syndrome or eosinophilic pneumonia may present upon steroid withdrawal, Arthralgia, rash, and serum sickness-like reactions, Helminth infection risk: patients at high risk may reactivate or acquire new infections |
| Food/Dietary | Avoid grapefruit juice as it may interact with omeprazole. Alcohol should be limited as it may increase risk of side effects. No specific dietary restrictions; however, taking with food may help reduce gastrointestinal upset. |
Loading safety data…
| Teratogenic Risk | OMLYCLO (clobazam) is a benzodiazepine. First trimester: Associated with oral clefts and congenital malformations in some studies. Second and third trimesters: Risk of CNS depression, hypotonia, respiratory depression, and withdrawal symptoms in neonates. Avoid use unless benefit clearly outweighs risk. |
| Fetal Monitoring | Regular fetal ultrasound for growth and anatomy; nonstress test and biophysical profile in third trimester; monitor maternal sedation and respiratory status; neonatal observation for withdrawal and CNS depression. |
| Fertility Effects | No specific studies in humans. In animal studies, no significant effects on fertility. However, benzodiazepines may cause menstrual irregularities and anovulation in some women. |
| Clinical Pearls | OMLYCLO (omeprazole and clarithromycin combination with amoxicillin) is used for Helicobacter pylori eradication. Monitor for Clostridioides difficile infection with prolonged antibiotic use. Clarithromycin may cause QT prolongation; caution with other QT-prolonging agents. Omeprazole may reduce absorption of vitamin B12 and magnesium with long-term use. |
| Patient Advice | Take this medication exactly as prescribed, usually twice daily for 14 days. · Complete the full course even if you feel better to ensure eradication of H. pylori. · May cause metallic taste or diarrhea; notify your doctor if severe or persistent. · Avoid alcohol and grapefruit juice during treatment as they may interact with medications. · If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose. |